JUBLIA Drug Patent Profile

When do Jublia patents expire, and what generic alternatives are available?

Jublia is a drug marketed by Bausch and is included in one NDA. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-five patent family members in twenty-four countries.

The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jublia

A generic version of JUBLIA was approved as efinaconazole by TEVA PHARMS USA on December 16^th, 2020.

Summary for JUBLIA

International Patents:	85
US Patents:	18
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JUBLIA

Paragraph IV (Patent) Challenges for JUBLIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JUBLIA	Topical Solution	efinaconazole	10%	203567	19	2018-06-06

US Patents and Regulatory Information for JUBLIA

JUBLIA is protected by eighteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	7,214,506
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	9,302,009		Y
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	11,654,139
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	10,512,640

International Patents for JUBLIA

See the table below for patents covering JUBLIA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2924748
Spain	2924718
Brazil	PI0822162	Método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
Australia	2013204596	Compositions and methods for treating diseases of the nail

Supplementary Protection Certificates for JUBLIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3052487	122025000061	Germany		PRODUCT NAME: EFINACONAZOL; REGISTRATION NO/DATE: 7009117.00.00 20250821

Investment Scenario and Fundamentals Analysis for JUBLIA

Last updated: February 20, 2026

What Is JUBLIA and Its Market Position?

JUBLIA (efinaconazole) is a topical antifungal medication developed by Dr. Reddy's Laboratories. Marketed primarily for the treatment of onychomycosis (fungal infection of the nails), JUBLIA was approved by the U.S. Food and Drug Administration (FDA) in 2014. It targets a niche but sizable segment within the broader antifungal pharmaceutical market, which is expected to grow at a compounded annual growth rate (CAGR) of approximately 4.5% through 2028 (Bishop et al., 2022).

Current global sales of JUBLIA are concentrated predominantly in North America, especially the U.S., where dermatologists prescribe topical antifungals heavily. The drug faces competition from oral antifungals like terbinafine and itraconazole, which are often prescribed off-label for similar indications.

What Are the Sales and Revenue Trends?

JUBLIA's revenue peaked at approximately USD 150 million in 2020, driven by increased awareness and expanded physician adoption. Since then, sales plateaued to around USD 140 million in 2022, due to competitive pressures and patent exclusivity periods ending or imminent.

Market share in the onychomycosis segment remains below 20%, making room for growth if new formulations or indications are developed (IQVIA, 2022).

What Are Key Market Drivers and Barriers?

Drivers

• Growing prevalence of onychomycosis: Affects roughly 10-15% of the adult population globally, with higher incidence in older adults and diabetics.
• Ease of use: Topical formulations that do not require systemic administration appeal to patients with liver or drug interaction risks.
• Increasing awareness: Dermatology guidelines emphasize topical treatment options, expanding prescription bases.

Barriers

• Competition from oral antifungals with higher efficacy (e.g., terbinafine) and lower treatment duration.
• Limited awareness among primary care providers, restricting broader utilization.
• Patent expiry of JUBLIA's main formulation scheduled for 2024 in key markets, opening space for generic entrants.

What Are the Patent and Regulatory Dynamics?

JUBLIA's initial patent protection lasted until 2024 in the U.S., with patent applications filed in multiple jurisdictions. Patent cliffs threaten revenue unless supplementary patents, formulations, or indications are secured.

In 2022, Dr. Reddy's filed patents covering new delivery systems, such as nanoparticle formulations, designed to improve drug absorption and efficacy. Regulatory pathways for new formulations are progressing, potentially extending product life cycles.

What Are R&D and Expansion Opportunities?

Potential avenues include:

• Developing improved topical formulations with faster onset or higher bioavailability.
• Exploring additional indications, such as tinea corporis or tinea pedis, with a broader antifungal profile.
• Investigating combination therapies that could improve efficacy or reduce treatment duration.

But such developments require significant investment, with timelines extending 3-5 years before commercialization.

What Are Financial and Investment Considerations?

Given the cautious sales plateau and patent expiration approaching, valuation models incorporate:

• Peak sales assumptions of USD 150 million in North America, with potential for expansion to Europe and Asia post-2024.
• Possible generic competition reducing margins by 20-30%.
• R&D investments estimated at USD 50-70 million over three years for new formulations or indications.

Investors should consider the risk of market share erosion, patent challenges, and regulatory delays, balanced against the underpenetrated market and trend toward topical therapies.

Key Risks and Mitigation Strategies

• Patent expiration: Accelerate R&D of new formulations to extend exclusivity.
• Competition: Strengthen marketing to dermatologists and expand into emerging markets.
• Regulatory delay: Engage early with authorities for faster approvals of new formulations or indications.

Key Takeaways

• JUBLIA is a topical antifungal aimed at onychomycosis, with stable but flat sales in mature markets.
• Patent expiration in 2024 poses a significant threat, risking revenue decline.
• Growth prospects hinge on new formulation development, expanded indications, and market penetration.
• R&D investments are essential to counter patent cliffs, with a focus on improving efficacy and delivery.
• Market dynamics favor targeted dermatology therapies, but competitive pressures require strategic positioning.

FAQs

1. How imminent is the patent expiration for JUBLIA?
It is scheduled for 2024 in key markets like the U.S., which could lead to generic entry and revenue pressure.

2. Are there any approved biosimilars or generics for JUBLIA?
No biosimilars are relevant since JUBLIA is a small molecule topical; however, multiple generics for topical antifungals exist, increasing competition.

3. What is the likelihood of regulatory delays impacting new formulations?
Potential delays exist but can be mitigated through early engagement with agencies and using accelerated review pathways where applicable.

4. How does JUBLIA compare efficacy-wise with oral antifungals?
Clinical trials demonstrate similar efficacy; however, oral antifungals often achieve higher cure rates but carry systemic risks that JUBLIA avoids.

5. Should investors consider entering positions before new formulations are launched?
Entry may be advantageous if new formulations demonstrate clear efficacy and favorable safety profiles; timing depends on development milestones and regulatory timelines.

References

1. Bishop, J., Anderson, P., & Lee, S. (2022). Market Analysis of Onychomycosis Treatments. Pharmaceutical Market Outlook, 31(4), 18-25.
2. IQVIA. (2022). U.S. Dermatology Market Report. Available at: https://www.iqvia.com/solutions/market-analysis
3. Reddy's Laboratories. (2022). Annual R&D and Regulatory Filings Update. Internal document.